Central Neck DissectionNCT07911761
Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma
An observational study of Central Neck Dissection and Papillary Thyroid Carcinoma, run by Mansoura University at 1 site in Egypt.
Trial summary
This study designed to examine the utility of prophylactic central neck dissection (CND) in the management of papillary thyroid carcinoma (PTC), to assess the association between risk factors as gender, age at diagnosis, and size of the tumor with performing central lymph node (CLN) affection, and to assess operative… Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Central Neck Dissection, Papillary Thyroid Carcinoma
- What is being tested?
- Thyroidectomy
- Type of treatment
- Surgery or procedure
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 1 May 2023to 1 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Study population: In this prospective follow-up study, 100 patients with papillary thyroid carcinoma was included.
Who may be able to join
- Age from 18 to 60 years old.
- Patient with papillary thyroid carcinoma.
Who cannot join
- Patients are unfit for surgery.
- Recurrence of thyroid cancer.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Role of Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma
This study designed to examine the utility of prophylactic central neck dissection (CND) in the management of papillary thyroid carcinoma (PTC), to assess the association between risk factors as gender, age at diagnosis, and size of the tumor with performing central lymph node (CLN) affection, and to assess operative time, intraoperative and postoperative adverse events of CLN neck dissection.
Read the detailed description
Thyroid cancer is the most common endocrine cancer, contributing to 1-2% of all new malignancies diagnosed yearly worldwide.
The majority of thyroid carcinomas originate from follicular epithelial cells and include well-differentiated papillary thyroid carcinomas, up to 80% of all thyroid malignancies and follicular thyroid carcinomas about 15% of all thyroid malignancies. Moreover, undifferentiated anaplastic thyroid carcinoma 1-2% of all thyroid cancers, which is the most aggressive thyroid malignancy, also develops from epithelial cells.
Some authors recommend routine central LN neck dissection (CND) in thyroid cancer to prevent a future recurrence, citing the high risk of positive lymph nodes, better outcomes, and a lower morbidity rate associated with this initial operation, whereas others maintain that this procedure increases the risk of injury to the parathyroid glands and recurrent laryngeal nerves, with no demonstrable benefits in terms of long-term survival.
- Being tested
- Thyroidectomy
- Medical subject headings
- Thyroid Cancer, Papillary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ThyroidectomyProcedure or surgery
Patients underwent total thyroidectomy with prophylactic bilateral central neck dissection.
| Study group | Role | What they receive |
|---|---|---|
| Study group | Patients With Clinically Node-Negative Papillary Thyroid Carcinoma Receives: Procedure: Thyroidectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Histopathologically Confirmed Occult Central Lymph Node Metastasis
Percentage of participants with clinically and radiologically node-negative papillary thyroid carcinoma who have metastasis detected by histopathological examination of central compartment lymph nodes removed during prophylactic bilateral central neck dissection.
Measured: 24 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Nov 2026
- Study start1 May 2023
- Primary completion1 May 2023
- Study completion1 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Central Neck DissectionStudies of the same condition, open and under way.
- More trials run by Mansoura UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mansoura University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Reda Ismail, Mansoura University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07911761
- Sponsor's protocol ID
- MS.23.03.2353
- Status last verified
- Oct 2026
- First submitted
- 28 Oct 2026
- Last updated
- 3 Nov 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Role of Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma
- ClinicalTrials.gov ID
- NCT07911761
- Acronym / sponsor ID
- MS.23.03.2353
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Mansoura UniversityUniversity, hospital or other
- Study start
- 1 May 2023 (actual)
- Primary completion
- 1 May 2023 (actual)
- Study completion
- 1 May 2025 (actual)
- First posted
- 3 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study designed to examine the utility of prophylactic central neck dissection (CND) in the management of papillary thyroid carcinoma (PTC), to assess the association between risk factors as gender, age at diagnosis, and size of the tumor with performing central lymph node (CLN) affection, and to assess operative time, intraoperative and postoperative adverse events of CLN neck dissection.
Detailed description
Thyroid cancer is the most common endocrine cancer, contributing to 1-2% of all new malignancies diagnosed yearly worldwide.
The majority of thyroid carcinomas originate from follicular epithelial cells and include well-differentiated papillary thyroid carcinomas, up to 80% of all thyroid malignancies and follicular thyroid carcinomas about 15% of all thyroid malignancies. Moreover, undifferentiated anaplastic thyroid carcinoma 1-2% of all thyroid cancers, which is the most aggressive thyroid malignancy, also develops from epithelial cells.
Some authors recommend routine central LN neck dissection (CND) in thyroid cancer to prevent a future recurrence, citing the high risk of positive lymph nodes, better outcomes, and a lower morbidity rate associated with this initial operation, whereas others maintain that this procedure increases the risk of injury to the parathyroid glands and recurrent laryngeal nerves, with no demonstrable benefits in terms of long-term survival.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study group | – | Procedure: ThyroidectomyPatients With Clinically Node-Negative Papillary Thyroid Carcinoma |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- In this prospective follow-up study, 100 patients with papillary thyroid carcinoma was included.
Key inclusion criteria (2 listed)
- Age from 18 to 60 years old.
- Patient with papillary thyroid carcinoma.
Key exclusion criteria (2 listed)
- Patients are unfit for surgery.
- Recurrence of thyroid cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ThyroidectomyPatients underwent total thyroidectomy with prophylactic bilateral central neck dissection. | Procedure or surgery | Study group |
Primary outcome
Percentage of Participants With Histopathologically Confirmed Occult Central Lymph Node Metastasis
Time frame: 24 hours postoperatively
Percentage of participants with clinically and radiologically node-negative papillary thyroid carcinoma who have metastasis detected by histopathological examination of central compartment lymph nodes removed during prophylactic bilateral central neck dissection.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Related trials for Central Neck Dissection
Not yet recruiting
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
Thyroid Gland Medullary Carcinoma
Not yet recruiting
The Role of Prophylactic Central Compartment Neck Dissection in the Management of 2 to 4 cm Papillary Thyroid Carcinoma
Papillary Thyroid Carcinoma, Central Compartment Neck Dissction
RecruitingObservational study
Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions
Esophageal Neoplasm, Esophageal Polyp
RecruitingObservational study
Targeting Real World Usage In Stroke Treatment
Saccular and Fusiform Aneurysms, Pseudoaneurysm
Active, not recruitingPhase 3
ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer
Thyroid Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Central Neck Dissection and Papillary Thyroid Carcinoma, run by Mansoura University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With Histopathologically Confirmed Occult Central Lymph Node Metastasis (time frame: 24 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.